Now Available On-Demand: CMV Stream 2025 – Advanced Strategies for CMV Management After Solid Organ Transplantation
CMV Stream 2025, brought to you by Kamada, features leading voices in transplantation for a dynamic, live expert panel discussion on “CMV Management in Solid Organ Transplantation: Insights and Challenges from the 4th International Consensus Guidelines on the Management of CMV in Solid Organ Transplantation”.
Hundreds of transplant professionals from the United States and more than 20 countries worldwide watched the live event, submitted questions, and shared their feedback.
This year’s esteemed panel included:
- Camille Kotton, MD | Massachusetts General Hospital / Harvard Medical School (USA)
- Atul Humar, MD, MSc, FRCPC | University Health Network (Canada)
- Lara Danziger-Isakov, MD, MPH | Cincinnati Children’s Hospital Medical Center (USA)
- Marcus Pereira, MD, MPH | Columbia University Irving Medical Center (USA)
- Erika Lease, MD, FCCP | University of Washington Medical Center (USA)
Together, they addressed the latest updates, key challenges and open questions from the 4th International Consensus Guidelines and explored evolving strategies in CMV prevention and management after solid organ transplantation.
Topics included:
- Best prevention methods, including novel agents
- Monitoring after prophylaxis or treatment
- Moving towards personalized management
- Interpretation of low-level viral loads
- Resistant CMV infections
- Use of immunoglobulins
The expert discussion was complemented by audience questions that reflected the practical challenges faced by clinicians worldwide. Kamada is proud to support CMV Stream as part of its ongoing commitment to enabling expert dialogue on CMV in the transplant setting. By fostering data-driven discussions and clinician-to-clinician exchange, Kamada helps advance the collective understanding of CMV management in high-risk patients.
The content of this recording was developed entirely by our industry partner, Kamada. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.